Tiny tumor models reshape the future of cancer medicine
Organoids, three-dimensional, patient-derived tumor models, are rapidly transforming oncology R&D.
)
Tiny models, big impact
Can tiny tumor models reshape the future of cancer medicine?
Yes, they can - and faster than many expect. Organoids, three-dimensional, patient-derived tumor models, are rapidly transforming oncology. They have become a transformative tool in cancer research: by mimicking tumor tissue, they provide more accurate, patient-relevant models, thereby enhancing patient-centric target validation, drug discovery, and clinical application.
In our most recent article “Tiny models, big impact” featured at European Biotechnology Magazine, Dr. Parvaneh Mohammadi, Director Primary Cell Modelling at Indivumed, shines a light on the transformative role of organoids in cancer R&D, its advantages and challenges: “Organoids can close the gap between basic science and clinical application. They help identify new therapeutic targets and can predict patient-specific responses to treatments, paving the way for more effective, individualized cancer therapies.”
We're happy to share the complete article published online at European Biotechnology Magazine.